Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPA_Options Trial
PACTR202507651010205Phase 2Recruiting
- Sponsor
- Advances Against Aspergillosis
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of posaconazole and amphotericin b in chronic pulmonary aspergillosis (CPA) (3 arms), sponsored by Advances Against Aspergillosis. Primary endpoints: Overall treatment success ordinal scale at 6 months, Body weight gain and 3 more. Started Sep 2025; status: recruiting.
02
Drugs
posaconazoleamphotericin b
03
Conditions
chronic pulmonary aspergillosis (CPA)
Beyond the preview
Go deeper on PACTR202507651010205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202507651010205.